Isomorphic Labs raised $2.1 billion in a funding round led by Thrive Capital to scale its artificial intelligence-driven drug discovery platform. The round included existing backers Alphabet and Google Ventures alongside new investors MGX, Temasek, and CapitalG (a new backer). This capital injection supports a broader industry push to use AI for shortening drug development timelines and reducing research costs.

Scaling the AlphaFold Legacy